One of the biggest tailwinds in the pharmaceutical industry is weight loss treatments. Breakthroughs in semaglutide and tirzepatide have given rise to several glucagon-like peptide-1 (GLP-1) medications, including Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound.While that is a long list of treatments, only two companies are the brains behind these blockbuster drugs: Novo Nordisk and Eli Lilly.Recently, a smaller company called Viking Therapeutics made waves in the weight loss scene following a successful ...

Some investors look at Pfizer (PFE -1.08%) as a has-been. That's understandable in some ways. Sales for the company's once-formidable COVID-19 franchise have tanked. So have Pfizer's overall revenue, profits, and share price.However, there's an argument that Pfizer is more of a "will-be" than a has-been. Could the drugmaker even be a trillion-dollar stock by 2035?How it could happenThe math is straightforward for how Pfizer could reach a market cap of $1 trillion over the next 11 or so years. Pfizer's marke ...

Pfizer (PFE) plans to sell 630 million ordinary shares of the consumer health company Haleon (HLN) , which it owns, in an underwritten offering. The sale of 630 million ordinary shares should be worth around $2.5 billion. Additionally, per a previous plan approved by Haleon shareholders, Pfizer will sell some shares worth approximately $400 million (£315 million) directly to Haleon.Haleon was a consumer health joint venture (JV), an over-the-counter (OTC) medicines business, jointly created by Pfizer and GS ...

Pfizer (PFE -0.68%) has seen its better days. Shares of the big drugmaker have plunged more than 50% from the highs set in late 2021. The pharma stock is down more than 30% over the last 12 months. Sales and profits have fallen sharply.Should investors avoid the beaten-down stock like the plague? I don't think so. Here are five reasons why buying this 6%-yielding dividend stock could be a brilliant move.1. COVID-19 troughMost of Pfizer's recent woes can be blamed on declining demand for its COVID-19 product ...

Angelo D'Amico/iStock via Getty Images Pfizer (NYSE:PFE) has had a rough few quarters. Following a massive boom in revenue and profits that was the direct result of the company's prominent Covid products - including the vaccine (Comirnaty) and Paxlovid - shares have plunged as the pandemic has broadly receded as a global threat: TradingView However, as Covid-based revenue and profit has moved from a big chunk of PFE's revenue to a comparably smaller piece of the pie, PFE's stock, at this point, has once ...

In this articlePGNYVTGNPFEPeathegee Inc | Tetra Images | Getty ImagesAfter years of being ignored, menopause has entered the public conversation.Celebrities from Drew Barrymore to Naomi Watts have opened up about symptoms and promoted products. Yet despite the increased chatter, there is a long way to go when it comes to treating symptoms — and a lot of opportunities for companies to step in to fill the gap.In fact, menopause is among the female health conditions with the highest unmet need and has "enormou ...

Pfizer (PFE) announced that the European Commission (EC) approved the label expansion of its 20-valent pneumococcal conjugate vaccine for use in infants, children and adolescents aged six weeks through 17 years of age.Following this decision, infants and children aged under 18 years can now be immunized with the Pfizer vaccine for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae).A pneumococcal infection is caused by the bacterium S. pneu ...

Pfizer (PFE) ended the recent trading session at $28.22, demonstrating a +0.75% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.19%. Elsewhere, the Dow saw an upswing of 0.1%, while the tech-heavy Nasdaq depreciated by 0.54%.The drugmaker's stock has climbed by 3.86% in the past month, exceeding the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18%.Market participants will be closely following the financial results of Pfizer in its upcoming release ...

Pfizer (PFE) announced positive overall survival data from a phase III study of Adcetris regimen in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) irrespective of CD30 expression.The ECHELON-3 study, evaluating Adcetris in combination with lenalidomide and rituximab, demonstrated a notable improvement in the primary endpoint of overall survival compared to the standard lenalidomide and rituximab plus placebo regimen. Moreover, secondary endpoints such as progression-free survival an ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. “The EC’s authorization of PREVENA ...